1. Drug-Drug Interactions in Older Cancer Patients
Examples of existing resources
to learn about DDI
Friday, November 13, 2015
Prague
Dr. Vincent Launay-Vacher, PharmD
Service ICAR
Pitié-Salpêtrière University Hospital
Paris - France

2. Disclosure last 3 years Direct Amgen Bayer Boehringer-Ingelheim
(honoraria, consulting, …)
Amgen
Bayer
Boehringer-Ingelheim
Hospira
Leo Pharma
Roche
Teva
Indirect
(research grants, grants to Service ICAR, …)
Daiichi-Sankyo
Gilead
Ipsen
Leo Pharma
Roche
Teva

3. DDI in clinical practice
Frequent
Potentially harmful for the patient:
Increased toxicity
Decreased efficacy
Even more frequent in the elderly: IPOP Study1
Community setting: non cancer patients, age ≥ 65
50 pharmacies / preliminary results on 488 patients
A mean of 7 different drugs (INN)
1Service ICAR – IPOP Study – Preliminary results, unpublished

4. IPOP Study
1Service ICAR – IPOP Study – Preliminary results, unpublished

5. Where to get information on DDI ?
Regulatory information: Summary of Product Characteristics (SmPC)
Vidal Dictionnary (France)
British National Formulary (UK)
Physician’s Desk Reference (USA)
EMA website: Example for Erlotinib (Tarceva®)

6. SmPC Tarceva®: EMA website

7. Where to get information on DDI ?
Regulatory information: Summary of Product Characteristics
Useful background information
Not very practical
Scientific Society: European Society of Medical Oncology (ESMO)
Has developed an online resource on DDI with Kinase Inhibitors
Released at the last European Cancer Congress in Vienna (September 2015)
Available on the ESMO Educational Portal: oncologypro.esmo.org

8. ESMO Educational Portal: oncologypro.esmo.org
In the Guidelines & Practice section
Focused on Kinase inhibitors DDI with other medicinal products

9. ESMO Educational Portal: oncologypro.esmo.org

10. ESMO Educational Portal: oncologypro.esmo.org

11. ESMO Educational Portal: oncologypro.esmo.org
Individual drug quick summaries:
Erlotinib
Imatinib
Pazopanib
Regorafenib
Sorafenib
Sunitinib
Vandetanib
Vemurafenib

12. ESMO Educational Portal: oncologypro.esmo.org
Files that can be downloaded for patients

13. ESMO Educational Portal: oncologypro.esmo.org

14. Where to get information on DDI ?
Regulatory information: Summary of Product Characteristics
Useful background information
Not very practical
Scientific Society: European Society of Medical Oncology (ESMO)
More practical
General although focused on Kinase inhibitors
Tools for patients and patient-HCP communication
Other website: SiteGPR®

15. SiteGPR®: www.sitegpr.com
In the Interaction tab
iMED
Specific booklets
One by drug
Kinase inhibitors

16. iMED on SiteGPR®: www.sitegpr.com
Sunitinib: iMED gives advices on DDI with 302 other drugs

17. All types of interaction
Pharmacodynamic
Metabolic
Transport

18. Where to get information on DDI ?
Regulatory information: Summary of Product Characteristics
Useful background information
Not very practical
Scientific Society: European Society of Medical Oncology (ESMO)
More practical
General although focused on Kinase inhibitors
Tools for patients and patient-HCP communication
Other website: SiteGPR®
Individual guides for each drug: iMED
Comprehensive resource (>300 DDIs analyzed)
More general tool: Drugs.com

19. Drug Interactions Checker: www.drugs.com
For HCP and patients
Allows multiple analyses and direct whole prescription analysis at once

20. Drug Interactions Checker: www.drugs.com
Two types of information:
for professionals
for patients
However, both are freely accessible

21. Drug Interactions Checker: www.drugs.com
Data on drug-food interaction are provided
only the pharmacodynamic DDI is presented

22. Where to get information on DDI ?
Regulatory information: Summary of Product Characteristics
Useful background information
Not very practical
Scientific Society: European Society of Medical Oncology (ESMO)
More practical
General although focused on Kinase inhibitors
Tools for patients and patient-HCP communication
Other website: SiteGPR®
Individual guides for each drug: iMED
Comprehensive resource (>300 DDIs analyzed)
More general tool: Drugs.com
Allows a whole prescription analysis at once
Probably not exhaustive in terms of DDI analyzed and presented
Provides data on drug-food interactions

23. Drug Interactions Checker
Summary
SmPC
DDI with KI
iMED®
Drug Interactions Checker
Regulatory
Not practical
More practical
Kinase inhibitors
Information for patients and communication tools
Practical: 1 guide per drug (iMED)
Comprehensive analyses
Practical: whole prescription analyzed
Not exhaustive
Provides data on drug-food interaction
Public
HCPs & Patients
HCPs only
ESMO members
Free registration
Source
Tool
Characteristics
Access

24. Thank you… …for your attention ! vincent.launay-vacher@aphp.fr